助手标题
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
共[58]条 当前为第1条到20条
 

相关语句
urological
    Objective: To evaluate the effect of U100plus laser lithotripsy on Urological calculi.
    目的:探讨U100plus激光碎石机治疗泌尿系结石的临床疗效。
    Methods: Eighty-one cases of urological stones were treated by U100plus laser lithotripsy.
    方法:对81例泌尿系结石患者行U100plus激光治疗,分析其碎石成功率及并发症。
    Conclusion: The U100plus laser lithotripsy is an effective and safe method for Urological calculi.
    结论:使用U100plus治疗泌尿系结石高效、安全。
    Method:The urinary nuclear matrix protein 22 was determined on 36 patients with bladder cancer,12 patients with benign urological disease and 20 healthy subjects by chemiluminescence.
    方法:应用化学发光分析法检测36例膀胱癌患者、12例泌尿系良性疾病组、20小便中的NMP22水平。
    Result:The median NMP22 value was respectively 1OOU/ml,16.7U/ml and 6. 5U/ml for bladder cancer, benign urological disease and healthy subjects. There were statistically different(P<0. 001). The 95% confidence interval was respectively 43.02-202.82U/ml,15.79-42.27U/ml and 5. 41-10. 82U/ml for each group.
    结果:36例膀胱肿瘤患者尿NMP22水平的中位值为100U/ml,同泌尿系良性疾病组(16.7U/ml)和正常对照组(6.5U/ml)相比较均具有极其显著性差异。
    Detection of Fas mRNA in urological malignant tissues
    Fas mRNA在泌尿系肿瘤组织中的表达
    Risk Factors of Urological Hospital Infection among Patients with a Single Disease: A Control Study
    单病种泌尿系医院感染危险因素对照研究
    Progress of MUC1 in urological malignancy
    MUC1在泌尿系肿瘤的相关研究进展
    Urological calculi treated with U100~(plus) laser lithotripsy
    泌尿系结石U100~(plus)激光碎石术
    Background and Objective:Renal cell carcinoma(RCC) is next most cancer in urological system.
    研究背景与目的肾癌(renal cell carcinoma)是泌尿系常见肿瘤,发病率仅次于膀胱肿瘤。
    Analysis of a series of renal functional test, special methods and clinical study, showed the possibility of prenatal diagnosis and the necessary of early treatment of congenital urological deformities.
    通过临床所见,尿液系列肾功能检查及特殊肾功能检查结果进行对比分析。 结果表明先天性泌尿系畸形产前诊断是可能的,早期治疗是必要的,并提出了早期手术的指征。
    Methods With reverse transcriptionpolymerase chain reaction (RTPCR),expresson of Fas mRNA was detected in 37 cases of urological malignant tissues,including 21 cases of renal cell carcinoma,11 cases of bladder carcinoma,4 cases of renal pelvis carcinoma and 1 case of prostatic sarcoma;
    方法采用逆转录PCR(RTPCR)法检测37例泌尿系恶性肿瘤组织中FasmRNA的表达,其中肾癌21例、膀胱癌11例、肾盂癌4例、前列腺肉瘤1例;
    Results:The median NMP22 value of urothelial cancer was 29.4 ×10 3 u/L,significantly higher than those of benign urological disease ( 10.1 ×10 3 u/L),other cancer ( 8.6 ×10 3 u/L) and healthy volunteer( 5.7 ×10 3 u/L)(P< 0.001 );
    结果 :尿路上皮癌组的尿 NMP2 2平均为 2 9.4× 1 0 3u/L,明显高于良性泌尿系疾病组 (1 0 .1× 1 0 3u/L )、其他恶性肿瘤组 (8.6× 1 0 3u/L)和健康志愿者组 (5.7× 1 0 3u/L) (P <0 .0 0 1 ) ;
    Results Median NMP22 va lue for the bladder cancers was 44.3 IU/L vs 5.8 IU/L for urological benign dise ases. The urinary NMP22 values in the bladder cancer group were significantly hi gher than those in the benign condition group (P<0.02).
    结果  18例膀胱癌患者尿NMP2 2的中位值为 44 .3IU/L ,2 0例泌尿系良性疾病患者尿NMP2 2的中位值为 5 .8IU/L ,二者相比差别有显著性意义 (P <0 .0 2 )。
    Methods:Using ELISA and radiommunoassay,the HA levels were measured in the urine specimens from 49 bladder cancer patients, 12 benign bladder tumor patients,30 no tumor urological patients and 20 normal controls.
    方法 :同时使用ELISA和放免两种方法对 49例膀胱移行细胞癌、1 2例良性膀胱肿瘤、30例良性前列腺增生 (BPH)和泌尿系结石以及 2 0例正常人尿液中HA含量进行检测 ,并将其结果与尿脱落细胞学检查结果进行比较。
    Results:The median NMP22 concentration measured in samples taken from group1,2,3 were 57.84×10 3U/L,9.95×10 3U/L,8.43×10 3U/L,respectively. The urinary NMP22 level recorded for patients with urothelial carcinoma was significantly higher than that noted for individuals with benign urological conditions and health subjects(P<0.05).
    结果 :膀胱癌患者尿中 NMP2 2水平 (5 7.84× 10 3U/ L)明显高于良性泌尿系疾病 (9.95× 10 3U/ L)和正常人群 (8.4 3× 10 3U/L ) ,有统计学意义 (P<0 .0 5 )。
    Methods:The level of CYFRA21-1was investigated with enzyme linked immunosorbent assay(ELISA)in the urine of63pa-tients,including35cases with bladder transitional cell carcinoma (groupⅠ),18with other urological pathological conditions(groupⅡ)and10free of urothelial disease(groupⅢ). Urinary CEA was also detected with enzyme immunoassay(EIA)in all patients.
    方法:用ELISA方法检测了35例膀胱移行细胞癌(Ⅰ组),18例泌尿系其它疾病(Ⅱ组),10例非泌尿系疾病患者(Ⅲ组)尿中CYFRA21-1的含量,同时用酶免疫法行尿CEA检测。
    Methods: Mcm5 in bladder carcinoma tissue and urine exfoliate cells in 70 patients with bladder cancer (25 cases of G1, 27 cases of G2, 18 cases of G3; 47 cases of Tis-T1, 23 cases of T2~T4), 40 patients with other urological diseases and 10 healthy volunteers were detected by using RT-PCR.
    方法:采用RTPCR方法检测70例膀胱肿瘤患者(G125例,G227例,G318例;TisT147例,T2~T423例)、40例泌尿系良性疾病患者和10例健康志愿者(正常对照组)尿脱落细胞中Mcm5的表达;
    THE PHASE ANALYSIS AND PREVENT ABOUT UROLOGICAL DEPARTMENT STONE
    泌尿系结石的物相分析与预防
    Serum TNF level in patients with urological malignancy
    泌尿系肿瘤患者血清中肿瘤坏死因子的水平及意义
 

首页上一页123下一页尾页 

 
CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社